As­traZeneca chops 210 work­ers, clos­es sites as it looks to con­cen­trate bi­o­log­ics man­u­fac­tur­ing in one place

As­traZeneca is clos­ing down two man­u­fac­tur­ing sites in Col­orado that col­lec­tive­ly em­ployed 210 work­ers, in an ap­par­ent ef­fort to con­sol­i­date its bi­o­log­ics sup­ply chain.

First re­port­ed in a WARN no­tice on Tues­day, the lay­offs are “un­re­lat­ed” to the or­ga­ni­za­tion­al changes an­nounced a day pri­or, spokesper­son Michele Meix­ell told me in an email.

The clo­sure of Boul­der and Long­mont is sim­ply a de­ci­sion to con­sol­i­date the bi­o­log­ics man­u­fac­tur­ing net­work in one large-scale drug sub­stance fa­cil­i­ty (our site cur­rent­ly op­er­at­ing in Fred­er­ick, MD) in or­der to im­prove ef­fi­cien­cy in our glob­al bi­o­log­ics sup­ply chain.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.